---
title: "Lysergide (DT120) in Generalized anxiety disorder: Voyage"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Voyage. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 78 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence/voyage"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Voyage

<a id="heading-3.1.1"></a>

## 3.1.1 Voyage

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Objective: efficacy and safety of a single 100 µg dose of DT120 versus placebo

> “To report topline efficacy and safety results from Voyage (NCT06741228), a phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating a single 100-μg dose of DT120 in adults with GAD”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.1-2"></a>

#### Registered official title

> “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.1-3"></a>

#### Part B objective: maintenance of efficacy and retreatment patterns

> “Part A evaluated acute efficacy and safety over 12 weeks following a single administration of DT120”
> “Part B evaluated the maintenance of efficacy and safety and retreatment patterns over an additional 40 weeks”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Sites: approximately 35 in the United States

> “The study enrolled 214 participants aged 18 to 74 years across approximately 35 sites in the United States”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.2-2"></a>

#### Registered locations: 34 sites in the United States

> “This study has 34 locations”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.2-3"></a>

#### Registered study dates

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2024-12-11” |
| Primary completion (actual) | “2026-07-15” |
| Study completion (estimated) | “2027-04” |
| Recruitment status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.2-4"></a>

#### First participant dosed: December 2024

> “today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

> “Initiated dosing in the Phase 3 Voyage study of MM120 ODT for the treatment of GAD in the fourth quarter of 2024.”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

<a id="topic-3.1.1.2-5"></a>

#### Topline results (Part A) reported: August 12, 2026

> “On August 12, 2026, we announced that the Voyage study met its primary endpoint and all key secondary efficacy endpoints”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.1.2-6"></a>

#### Topline timing: early third quarter of 2026, February to May 2026, superseded in August 2026

> “Topline data are anticipated in early 3Q 2026.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “In December 2024, we announced the initiation of Voyage, and we anticipate a topline readout (Part A results) in early third quarter 2026.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “Topline data expected in early 3Q 2026.”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.1.2-7"></a>

#### Topline timing: second quarter of 2026, January 2026, superseded in February 2026

> “2Q 2026: Topline data from Voyage – the first Phase 3 study of DT120 ODT in GAD”

Source: [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)

<a id="topic-3.1.1.2-8"></a>

#### Topline timing: first half of 2026, March to November 2025, superseded in January 2026

> “Topline data from the 12-week double-blind period (Part A) is anticipated in the first half of 2026.”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates); [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

> “Topline data for Voyage is expected in the first half of 2026 and for Panorama and Emerge in the second half of 2026.”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Design: phase 3, multicenter, randomized, double-blind, placebo-controlled

> “Voyage is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a single 100 µg dose of DT120 ODT versus placebo in adults with generalized anxiety disorder (GAD). The study consists of a 12-week double-blind period (Part A) followed by a 40-week open-label extension (Part B), during which participants may be eligible to receive up to four additional doses of DT120 ODT based on symptom severity.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.3-2"></a>

#### Part A and Part B: 12-week parallel-group period and 40-week extension

> “Both trials are comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel-group trial assessing the efficacy and safety of DT120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with DT120 ODT, subject to certain conditions for treatment eligibility.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.1.3-3"></a>

#### Randomization: 1:1 to DT120 or placebo

> “The study consisted of a 12-week, randomized, double-blind, single-dose administration period in which participants were randomized 1:1 to DT120 or placebo (Part A), followed by a 40-week extension phase where participants had the opportunity for open-label treatment (Part B; Figure 1)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Two-arm framework without a low-dose comparator

> “Voyage and Emerge established a 2-arm framework of DT120 100 μg versus placebo to characterize target dose efficacy and safety. Panorama and Ascend added DT120 50 μg as a low-dose comparator, thereby creating a 3-arm framework to evaluate efficacy and safety as well as mitigate functional unblinding (Figure 1)”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.3-5"></a>

#### Masking: participants and treating clinicians, identical placebo tablet

> “This study is double-blinded, which means that both the participants and the treating clinicians will be masked to treatment allocation, meaning neither party will know which participants are receiving the active drug and which are receiving the placebo. The placebo tablet is identical looking to the active drug”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.3-6"></a>

#### Central raters blinded to treatment assignment and visit number

> “In Voyage, HAM-A ratings were assessed by central raters blinded to both treatment assignment and visit number.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “Participants, DSMs, central raters, and dosing sites were blinded to treatment and primary endpoint data”
> “HAM-A (GAD) or MADRS (MDD) central raters were independent from the dosing site and blinded to treatment and visit number”
> “Site raters could not serve as the DSM or HCP for the same participant after the screening or baseline assessments to mitigate functional unblinding”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.3-7"></a>

#### Expectancy and perceived treatment assessment

> “Baseline expectancy was measured in participants, and perceived treatment was recorded for both participants and central raters”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.3-8"></a>

#### Standalone drug effect without psychotherapy

> “The design of the MM120 ODT Phase 3 clinical program directly builds on the robust Phase 2b study results and incorporates best-in-class methodologies to mitigate the impact of functional unblinding, including the use of independent central raters blinded to both treatment assignment and visit number. The studies have also been designed to isolate the standalone drug effect of MM120 ODT from other psychotherapeutic intervention and follow industry best practices for safety monitoring.”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.1.3-9"></a>

#### Adaptive design: blinded interim sample size re-estimation

> “Both trials use an adaptive trial design with a blinded interim sample size re-estimation (“SSRE”), allowing for an increase in sample size by up to 50% in each trial depending on the observed values for certain nuisance parameters.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-3.1.1.3-10"></a>

#### Part B: symptom-triggered open-label treatment

> “Open-label treatment in Part B was based on prespecified symptom severity, which allowed for assessment of retreatment patterns and durability of response in a real-world fashion (Figure 2)”
> “To maintain data integrity, participants who met retreatment thresholds and had no safety concerns were required to re-treat”
> “Total of up to 5 doses over 52-week period with final dose no later than week 50.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.3-11"></a>

#### Part B: follow-up observation and retreatment threshold

> “GAD-7 (ePRO): biweekly”
> “HAM-A (central rater): monthly or when GAD-7 ≥10”
> “Eligible for open-label treatment if HAM-A ≥16”
> “Up to 4 open-label doses of DT120 ODT 100 µg”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Inclusion criteria: registry record

> “Diagnosis of GAD per DSM-5”
> “Male or female aged 18 to 74”
> “HAM-A Total Score ≥20”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.4-2"></a>

#### Exclusion criteria: registry record

> “Certain psychiatric disorders (other than generalized anxiety disorder)”
> “First degree relative with or lifetime history of a psychotic disorder or bipolar disorder”
> “Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)”
> “Any clinically significant unstable illness”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.4-3"></a>

#### Diagnosis confirmed by the Mini-International Neuropsychiatric Interview

> “with a DSM-5-confirmed diagnosis of GAD, based on clinical assessment and the Mini-International Neuropsychiatric Interview (MINI), and a Hamilton Anxiety Rating Scale (HAM-A) total score of at least 20 at screening and baseline”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.4-4"></a>

#### Key inclusion criteria: Voyage and Panorama

> “GAD diagnosis based on DSM-5 and confirmed by MINI”
> “HAM-A total score ≥20 at screening and baseline”
> “MADRS items 1, 7, and 8 score ≤3 at screening and baseline”
> “Use of highly effective methods of contraception”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.4-5"></a>

#### Key exclusion criteria: Voyage and Panorama

> “Contraindicated medical or psychiatric conditions”
> “Systematic psychotherapy ≤4 weeks prior to screening or plans to initiate therapy”
> “Use of prohibited concomitant medications, supplements, or other therapeutics”
> “>10 instances of psychedelics use in the past 5 years and any use in the past 2 years”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.4-6"></a>

#### Prior psychedelic use criterion amended to any lifetime use

> “Exclusion criteria related to prior use of psychedelics was later amended to any lifetime use of psychedelics based on FDA feedback.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.4-7"></a>

#### Concomitant medications with interaction potential or anxiolytic or antidepressant effects

> “Participants were excluded if they had medical or psychiatric conditions that were contraindicated, or if they were taking concomitant medications, supplements, or other therapeutics with potential drug–drug interactions or anxiolytic or antidepressant effects that could not be discontinued”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.4-8"></a>

#### Independent review of eligibility

> “Eligibility criteria were reviewed independently by site personnel, central raters, and medical monitors, thereby enhancing diagnostic accuracy and reducing site-level variability (Table 1)”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Arms: DT120 100 µg or placebo

> “Placebo Comparator: Arm 1 - Placebo”
> “Experimental: Arm 2 - 100µg DT120”
> “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.5-2"></a>

#### Single administration of DT120 ODT 100 µg in Part A

> “Of these, 214 participants were randomized 1:1 to receive a single administration of 100 µg of DT120 (n = 107) or placebo (n = 107; Table 1)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.5-3"></a>

#### Open-label doses in Part B

> “40-week extension with opportunity for open-label DT120 100 µg based on protocol-defined symptom and safety criteria; up to 4 Part B doses (max 5 total doses over 52 weeks)”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.5-4"></a>

#### Dosing session monitors and psychotherapy

> “Two qualified and trained DSMs monitored dosing, with the second DSM having the option to monitor remotely via video. A total of 3 DSMs were onsite, and a licensed HCP was available or on call ≤15 minutes from the site”
> “Psychotherapy was prohibited during dosing sessions. Standardized EoSC was used to assess participant status and ability to end the dosing session”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-3.1.1.5-5"></a>

#### End-of-session checklist: hourly from hour 5 after dosing

> “On the day of dosing, participants were assessed hourly beginning at hour 5 post-dose on a structured end-of-session checklist (EoSC).”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The EoSC is an 8-question checklist used to assess participant readiness for completion of monitoring after receiving DT120.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.5-6"></a>

#### Required monitoring period in the pivotal studies: 8 hours

> “Required monitoring period for all participants in pivotal studies is 8 hours and requires that participants clear the End of Session Checklist.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Hamilton Anxiety Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint: change in HAM-A total score at Week 12

> “The primary endpoint is change from baseline in HAM-A total score at Week 12. Key secondary multiplicity-controlled endpoints are change from baseline in Clinical Global Impression-Severity (CGI-S) scale score at Week 12, change from baseline in HAM-A total score at Week 1, and change from baseline in CGI-S score at Day 2.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.6.1-2"></a>

##### Week 12 timepoint based on the durability observed in the phase 2b study

> “The primary endpoint of Voyage will measure the change from baseline in HAM-A at Week 12, which is consistent with the durable clinical effect observed in the Phase 2b study.”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-3.1.1.6.1-3"></a>

##### HAM-A: 14-item clinician-rated scale, range 0 to 56

> “The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

> “The HAM-A is a 14-item clinician-rated outcome measure assessing various domains of anxiety with a range of 0–56.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.6.1-4"></a>

##### Minimal clinically important difference and dose selection from the phase 2b study

> “The minimal clinically important difference was 2.5 points.”
> “These findings support the selection of 100-µg dose of MM120 for pivotal trials to assess its efficacy, durability, and safety in the treatment of GAD.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-3.1.1.6.1-5"></a>

##### Secondary endpoints: HAM-A response, remission, and mild or better at Week 12

> “HAM-A response (≥50% improvement) at week 12”
> “HAM-A remission (total score ≤7) at week 12”
> “HAM-A mild or better (total score <16) at week 12”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.6.1-6"></a>

##### Clinical Global Impression-Severity: range 1 to 7

> “The CGI-S is a clinician-rated outcome measure assessing overall severity of illness with a range of 1 to 7.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.6.1-7"></a>

##### Registered secondary endpoints: patient-reported outcomes, functioning, and quality of life

> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)”
> “Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period”
> “Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-3.1.1.6.1-8"></a>

##### Registered secondary endpoints: retreatment in Part B

> “Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period”
> “Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Enrolled: 214 participants randomized 1:1

> “Completed enrollment in Voyage (GAD) with 214 participants randomized 1:1 to receive DT120 ODT 100 µg or placebo.”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-3.1.1.7.1-2"></a>

##### Sample size re-estimation: no increase required

> “The SSRE for Voyage has been completed and it was determined that no increase in the sample size of the trial is required.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “The protocol-specified blinded sample size re-estimation is complete, requiring no increase in enrollment.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

<a id="topic-3.1.1.7.1-3"></a>

##### Analyzed: all randomized participants in the intention-to-treat population

| Arm | Randomized | Analysis population |
| --- | --- | --- |
| DT120 ODT | “n=107” | “100% included in ITT population” |
| Placebo ODT | “n=107” | “100% included in ITT population” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.1-4"></a>

##### Planned enrollment: approximately 200 participants, December 2024 to February 2026, superseded in May 2026

> “Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT versus placebo and is expected to enroll approximately 200 participants in the United States.”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

> “Voyage is expected to enroll approximately 200 participants in the U.S. randomized 1:1 to receive DT120 ODT 100 µg or placebo.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Primary analysis: mixed-effects model for repeated measures with reference-based imputation, ITT population

> “Primary endpoint of the study was change from baseline in HAM-A at week 12 using a mixed-effects model repeated-measures statistical analysis with reference-based imputation.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “Source: Voyage study documents. ITT population.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Multiplicity control: hierarchical testing of key secondary endpoints

> “Includes the primary endpoint and all hierarchically controlled key secondary endpoints.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.2-3"></a>

##### Safety population: Part A through Week 12

> “Source: Voyage study documents. Safety population in study part A (through week 12).”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.2-4"></a>

##### Subgroup analyses: same model as the primary analysis

> “For each subgroup, the change from baseline in HAM-A total score is analyzed using the same MMRM model as the primary efficacy analysis. If the number of patients is small for a subgroup, the treatment difference will not be stable as it would be highly sensitive to outliers.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.7.2-5"></a>

##### Part B interim analysis: extension population and ITT Part A+B population

> “Extension population includes participants with at least one Part B visit completed.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

> “Based on interim analysis as of July 15, 2026.  ITT Part A+B population with treatment policy strategy.  Interim analysis based on partial data and subject to change.”
> “n is the number of participants in the ITT Part A+B population with non-missing HAM-A score at Baseline and the respective visit.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Screened and randomized

> “A total of 845 participants were screened for eligibility. Of these, 214 participants were randomized 1:1 to receive a single administration of 100 µg of DT120 (n = 107) or placebo (n = 107; Table 1)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.1-2"></a>

##### Part A completion

| Arm | Randomized | Completed Part A |
| --- | --- | --- |
| DT120 ODT | “n=107” | “90% completed Part A” |
| Placebo ODT | “n=107” | “88% completed Part A” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.1-3"></a>

##### Overall discontinuation: 10% and 12%

> “Overall discontinuation rates were similar between DT120 ODT 100 µg and placebo groups (10% and 12%).”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.1.8.1-4"></a>

##### Part B interim disposition as of July 15, 2026

| Part A arm | Part B extension population | Through Week 28 | Through Week 36 | Through Week 52 |
| --- | --- | --- | --- | --- |
| DT120 ODT | “n=90” | “Through Week 28 (n=44)” | “Through Week 36 (n=31)” | “Through Week 52 (n=14)” |
| Placebo ODT | “n=87” | “Through Week 28 (n=53)” | “Through Week 36 (n=30)” | “Through Week 52 (n=8)” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

> “Based on interim analysis as of July 15, 2026.  Interim analysis based on partial data and subject to change.”
> “Extension population includes participants with at least one Part B visit completed.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Demographics and baseline characteristics: ITT population

| Characteristic | DT120 ODT (n = 107) | Placebo ODT (n = 107) | Overall (N = 214) |
| --- | --- | --- | --- |
| Age, mean (range), years | “42 (21–72)” | “43 (20–67)” | “42 (20–72)” |
| Female, n (%) | “63 (59)” | “74 (69)” | “137 (64)” |
| Male, n (%) | “44 (41)” | “33 (31)” | “77 (36)” |
| White, n (%) | “78 (73)” | “77 (72)” | “155 (72)” |
| Black or African American, n (%) | “9 (8)” | “19 (18)” | “28 (13)” |
| Asian, n (%) | “8 (7)” | “9 (8)” | “17 (8)” |
| Baseline HAM-A score, mean (SD) | “28.4 (5.9)” | “27.4 (5.5)” | “27.9 (5.7)” |
| Moderate GAD (HAM-A <24), n (%) | “26 (24)” | “28 (26)” | “54 (25)” |
| Severe GAD (HAM-A ≥24), n (%) | “81 (76)” | “79 (74)” | “160 (75)” |
| Baseline CGI-S score, mean (SD) | “4.6 (0.6)” | “4.6 (0.6)” | “4.6 (0.6)” |
| Past use of any psychedelic, n (%) | “18 (17)” | “27 (25)” | “45 (21)” |
| Past LSD use, n (%) | “10 (9)” | “9 (8)” | “19 (9)” |
| No past GAD medications, n (%) | “35 (33)” | “36 (34)” | “71 (33)” |
| One past GAD medication, n (%) | “31 (29)” | “34 (32)” | “65 (30)” |
| Two or more past GAD medications, n (%) | “41 (38)” | “37 (35)” | “78 (36)” |
| Comorbid MDD, n (%) | “43 (40)” | “37 (35)” | “80 (37)” |
| Years since GAD diagnosis, mean (SD) | “11.1 (10.1)” | “12.9 (11.6)” | “12.0 (10.9)” |
| Years since onset of GAD symptoms, mean (SD) | “21.9 (13.7)” | “25.7 (14.4)” | “23.8 (14.1)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Severity categories and psychedelic definitions

> “Eligibility criteria required a baseline HAM-A score of ≥20; moderate symptoms are defined as a HAM-A score of 16–23.”
> “Psychedelics include LSD, psilocybin, dimethyltryptamine, and other classic serotonergic psychedelics.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Baseline MADRS score

| Characteristic | DT120 ODT (n=107) | Placebo ODT (n=107) | Overall (n=214) |
| --- | --- | --- | --- |
| MADRS score, mean (SD) | “13.6 (4.6)” | “13.5 (4.4)” | “13.5 (4.5)” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.2-4"></a>

##### Characteristics at Part B entry: interim analysis

| Characteristic | DT120 ODT in Part A (n=62) | Placebo ODT in Part A (n=75) | Total (n=137) |
| --- | --- | --- | --- |
| Mean age (years) | “40.9” | “43.6” | “42.3” |
| Sex, female (%) | “52%” | “68%” | “61%” |
| Race (% white) | “76%” | “76%” | “76%” |
| HAM-A score at Part B entry | “16.8” | “21.2” | “n/a” |
| CGI-S score at Part B entry | “3.6” | “4.2” | “n/a” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

> “ITT population who entered Part B. Data based on Week 12 in Part A.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Primary and key secondary endpoints: Part A

| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A: LS mean change at Week 12 (primary) | “-11.6” | “-6.2” | “-5.4 (p<.0001)” |
| CGI-S: LS mean change at Week 12 (key secondary) | “-1.0” | “-0.4” | “-0.6 (p<.0001)” |
| HAM-A: LS mean change at Week 1 (key secondary) | “-11.9” | “-4.2” | “-7.7 (p<.0001)” |
| CGI-S: LS mean change at Day 2 (key secondary) | “-1.0” | “-0.2” | “-0.8 (p<.0001)” |

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.8.3-2"></a>

##### Primary endpoint: effect size d=0.81

> “The Least Squares (LS) mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -11.6 compared with -6.2 for participants who received placebo, an LS mean difference of -5.4 points (p<0.0001), corresponding to a standardized effect size of d=0.81. Efficacy was rapid, with changes seen as early as Day 2 and sustained at all post-baseline timepoints in Part A.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.8.3-3"></a>

##### Response, remission, and mild or better at Week 12

| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A response rate (≥50%) at Week 12 | “43%” | “16%” | “27% (p<0.0001)” |
| HAM-A remission rate (≤7) at Week 12 | “14%” | “4%” | “10% (p=0.0222)” |
| HAM-A mild or better (<16) at Week 12 | “51%” | “23%” | “28% (p<0.0001)” |

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.8.3-4"></a>

##### HAM-A change from baseline by visit

| Visit | DT120 ODT: change from baseline | Improvement over placebo |
| --- | --- | --- |
| Week 1 | “Week 1: −11.9 points” | “Week 1: −7.7 points” |
| Week 4 | “Week 4: −12.5 points” | “Week 4: −6.8 points” |
| Week 8 | “Week 8: −12.1 points” | “Week 8: −5.5 points” |
| Week 12 | “Week 12: −11.6 points” | “Week 12: −5.4 points” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.3-5"></a>

##### CGI-S change from baseline by visit

| Visit | DT120 ODT: change from baseline | Improvement over placebo |
| --- | --- | --- |
| Day 2 | “Day 2: −1.0 points” | “Day 2: −0.8 points” |
| Week 1 | “Week 1: −1.4 points” | “Week 1: −1.1 points” |
| Week 4 | “Week 4: −1.3 points” | “Week 4: −0.7 points” |
| Week 8 | “Week 8: −1.1 points” | “Week 8: −0.6 points” |
| Week 12 | “Week 12: −1.0 points” | “Week 12: −0.6 points” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.3-6"></a>

##### Subgroup analyses: placebo-adjusted change in HAM-A at Week 12

| Subgroup | Placebo-adjusted change in LS mean (SE) |
| --- | --- |
| All participants | “−5.4 (1.0)” |
| Time since GAD symptoms began <22 years (n = 107) | “−5.9 (1.4)” |
| Time since GAD symptoms began ≥22 years (n = 107) | “−4.7 (1.5)” |
| Previous GAD medications <2 (n = 136) | “−4.2 (1.2)” |
| Previous GAD medications ≥2 (n = 78) | “−5.6 (1.7)” |
| Male (n = 77) | “−7.1 (1.7)” |
| Female (n = 137) | “−5.5 (1.2)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “The treatment effect was maintained across key subgroups, including in participants with ≥2 previous trials of medications for GAD (Figure 5)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.3-7"></a>

##### Part B interim: response, remission, and mild or better through Week 28 among participants given DT120 in Part A

| Visit | n | HAM-A improvement ≥50% | HAM-A ≤7 | HAM-A <16 |
| --- | --- | --- | --- | --- |
| Week 12 | “94” | “44%” | “14%” | “51%” |
| Week 16 | “62” | “31%” | “11%” | “45%” |
| Week 20 | “55” | “44%” | “13%” | “46%” |
| Week 24 | “41” | “51%” | “15%” | “61%” |
| Week 28 | “37” | “60%” | “24%” | “65%” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

> “Source: Voyage study documents. Based on interim analysis as of July 15, 2026.  ITT Part A+B population.  Interim analysis based on partial data and subject to change.”
> “Only includes participants who received DT120 ODT in Part A”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Adverse event overview: Part A safety population

| Adverse event | DT120 ODT (n = 107) | Placebo ODT (n = 107) |
| --- | --- | --- |
| Any TEAE, n (%) | “106 (99)” | “74 (69)” |
| Mild | “65 (61)” | “49 (46)” |
| Moderate | “41 (38)” | “24 (22)” |
| Severe | “0” | “1 (1)” |
| Any study drug–related TEAE, n (%) | “102 (95)” | “51 (48)” |
| Any AESI, n (%) | “100 (93)” | “30 (28)” |
| Any treatment-emergent SAE, n (%) | “0” | “3 (3)” |
| Any TEAE leading to discontinuation, n (%) | “1 (1)” | “0” |
| Any TEAE leading to death, n (%) | “0” | “0” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “AEs were collected in accordance with FDA final guidance for psychedelic drug development, which includes expected effects characterized as positive, favorable, or neutral.”
> “Severe AE was diverticulitis, occurring approximately 9 weeks after dose.”
> “Participant discontinued due to recurrence of depression approximately 6 weeks after dose.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-3.1.1.8.5-2"></a>

##### Adverse events of special interest: topline presentation value

| Adverse event | DT120 ODT (n=107) | Placebo ODT (n=107) |
| --- | --- | --- |
| Any Adverse Event of Special Interest (AESI) | “100 (94%)” | “30 (28%)” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.5-3"></a>

##### Severity, timing, and most common adverse events

> “DT120 was generally well tolerated. No serious adverse events (AEs), suicidal behavior, or self-injurious behavior were reported during Part A of the study”
> “All AEs reported for DT120 ODT were mild to moderate in severity (Table 2). The most common treatment-emergent AEs (TEAEs) were illusion, nausea, and euphoric mood. The majority of TEAEs occurred on the dosing day. The most common TEAE reported after the dosing day was headache”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “DT120 ODT 100 µg was generally well tolerated, with treatment-emergent adverse events (“TEAEs”) mild to moderate in severity, transient, and predominantly occurring on the day of dosing in Part A. No new safety signals were identified, including no suicidality signal or suicidal behavior. There were no drug-related serious adverse events in Part A.”
> “The overall TEAE rate for DT120 ODT 100 µg and placebo was 99% and 69%. The most common TEAEs (>10%) in the DT120 ODT 100 µg arm on dosing day were illusion (75%), nausea (38%), euphoric mood (26%) and headache (24%).”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-3.1.1.8.5-4"></a>

##### TEAEs with incidence of 10% or more, on the dosing day and after it

| TEAE | Dosing day: DT120 ODT (n=107) | Dosing day: placebo ODT (n=107) | After dosing day: DT120 ODT (n=107) | After dosing day: placebo ODT (n=107) |
| --- | --- | --- | --- | --- |
| Illusion | “80 (75%)” | “11 (10%)” | “2 (2%)” | “0” |
| Nausea | “41 (38%)” | “9 (8%)” | “3 (3%)” | “3 (3%)” |
| Euphoric mood | “28 (26%)” | “4 (4%)” | “0” | “0” |
| Headache | “26 (24%)” | “7 (7%)” | “12 (11%)” | “7 (7%)” |
| Feeling abnormal | “21 (20%)” | “3 (3%)” | “0” | “0” |
| Disorientation | “19 (18%)” | “2 (2%)” | “1 (1%)” | “0” |
| Dizziness | “14 (13%)” | “5 (5%)” | “1 (1%)” | “1 (1%)” |
| Crying | “13 (12%)” | “4 (4%)” | “0” | “0” |
| Thinking abnormal | “12 (11%)” | “1 (1%)” | “0” | “0” |
| Paraesthesia | “12 (11%)” | “4 (4%)” | “0” | “0” |
| Feeling of body temperature change | “12 (11%)” | “1 (1%)” | “0” | “0” |
| Anxiety | “11 (10%)” | “2 (2%)” | “3 (3%)” | “0” |
| Feeling of relaxation | “8 (8%)” | “12 (11%)” | “1 (1%)” | “0” |
| Hallucination, visual | “9 (8%)” | “2 (2%)” | “1 (1%)” | “0” |
| Insomnia | “7 (7%)” | “0” | “1 (1%)” | “6 (6%)” |
| Emotional disorder | “6 (6%)” | “1 (1%)” | “1 (1%)” | “0” |

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.5-5"></a>

##### Suicidality: Columbia-Suicide Severity Rating Scale

> “Participant suicidality assessment based on changes in C-SSRS.”
> “No suicidal or self-injurious behavior”
> “No indication of increased suicide-related risk”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.5-6"></a>

##### Serious adverse events across DT120 studies, including Part B of Voyage, as of September 14, 2026

> “As of September 14, 2026, a total of 14 participants reported a treatment emergent serious adverse event across all studies of DT120, including 1 SAE deemed treatment-related in Part B of Voyage, resulting in an SAE rate of approximately 1.45%”
> “Part B safety data are expected to be shared in a future presentation.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-3.1.1.8.5-7"></a>

##### Serious adverse events across DT120 studies, August 2026, superseded in November 2026

> “At the time of the analysis, a total of 13 participants reported a treatment emergent serious adverse event across all studies of DT120 ODT, including 1 SAE deemed treatment-emergent in Part B of Voyage, resulting in an SAE rate of approximately 1.7% across studies and populations.”

Source: [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)

<a id="topic-3.1.1.8.5-8"></a>

##### End-of-session checklist clearance: topline announcement, August 2026

> “The average time to meeting EoSC criteria was 6.4 hours for participants receiving DT120 ODT in Part A, with a median of 6.1 hours and 92% of participants meeting the EoSC criteria by hour 8.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-3.1.1.8.5-9"></a>

##### End-of-session checklist clearance: Psych Congress poster, September 2026

> “Average time to End-of-Session Checklist (EoSC) clearance was 6.4 hours (Figure 6). More than half of participants met all EoSC criteria at hour 6, and the majority of participants (90%) met all EoSC criteria by hour 8”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- Publication status: results come from company topline announcements, presentations, and filings and from a report of the Voyage topline results; one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results.
- Functional unblinding: Voyage used a two-arm design of DT120 100 µg versus placebo without the 50 µg low-dose comparator used in Panorama. Study drug-related TEAEs occurred in 95% of participants receiving DT120 and 48% receiving placebo, and illusion occurred on the dosing day in 75% and 10%. Baseline expectancy and perceived treatment were recorded; the cited disclosures report no results of these assessments. Central HAM-A raters were blinded to treatment assignment and visit number. Past psychedelic use was reported by 21% of participants.
- Duration and dosing: the controlled comparison covers 12 weeks after a single dose. Part B is open label, and its results come from an interim analysis as of July 15, 2026, with 37 participants who received DT120 in Part A contributing HAM-A data at Week 28.
- Comparator: placebo was the only comparator; no active GAD treatment was included. The placebo group improved by 6.2 points on HAM-A at Week 12.
- Generalizability: participants were 18 to 74 years of age at approximately 35 sites in the United States, and people taking medications with anxiolytic or antidepressant effects that could not be discontinued, people with a personal or first-degree family history of psychotic or bipolar disorder, people with current alcohol or substance use disorder, and people in systematic psychotherapy within 4 weeks before screening were excluded.
- Outcomes not reported in the cited disclosures: registered patient-reported, functioning, quality of life (PGI-S, WPAI-SHP, EQ-5D-5L), and sexual functioning (CSFQ-14) endpoints. The sponsor stated that Part B safety data are expected to be shared in a future presentation.
- Discrepancies between sources: the share of participants clearing the end-of-session checklist by hour 8 is 92% in the topline announcement and 90% in the poster, and adverse events of special interest with DT120 are 100 (94%) in the topline presentation and 100 (93) in the poster.

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf); [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
